|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.69 / 14.81|
Two-Year Extension Follows Completion of $8 Million Upgrade and Preparation for Re-Launch of Alferon N in the US
New Program Launched in Concert With Facilities Enhancement
Seasoned Executive With Extensive International Experience
Hemispherx and Emerge Health to Commence a Named Patient Program While Seeking Formal Regulatory Approval
Planned Launch of Alferon N Injection(R) Highlighted
Newly Upgraded Alferon Facility Completed; Production of New Alferon API Inventory Commenced in February 2015; Our European Subsidiary Received Formal Notification of Approval of Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)
Important Step in Hemispherx's Antiviral Program
These under-$10 biotech stocks are within range of triggering breakout trades.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Stocks with insider trader activity include NDAQ, FEYE and HEB
Stocks with insider trader activity include KCG, HEB and OXM
Stocks with insider trader activity include HEB, MS and IMPV
Stocks with insider trader activity include FTD, HEB and AWH
Hemispherx' Next Step in the Fight to Treat Patients With EVD
In Vivo Data at 7th International Symposium on Filoviruses, March 25-March 28, 2015 in Washington, DC
Newly Upgraded Alferon(R) Facility Completed; Production of New Alferon(R) API Inventory Commenced in February 2015
Since the end of September, Hemispherx sold almost 25 million shares of company stock, equivalent to the amount of stock sold in the first nine months of 2014.
Hemispherx and Emerge Health to Commence Named Patient Sales While Seeking Formal Regulatory Approval
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.